Annals of Hematology最新文献

{"title":"An assessment of the effectiveness of hydroxyurea therapy in children and adolescents with sickle cell anaemia at Kenyatta National Hospital","authors":"Madline Yacoub-Kenyi Leju,&nbsp;Amsalu Degu","doi":"10.1007/s00277-026-07156-0","DOIUrl":"10.1007/s00277-026-07156-0","url":null,"abstract":"<div><p>Sickle cell anaemia (SCA) is a major public health concern in Kenya, particularly affecting children and adolescents. Despite the inclusion of hydroxyurea in national treatment guidelines, its real-world use and effectiveness in Kenya remain under-documented, especially in tertiary care settings such as Kenyatta National Hospital (KNH). The drug is known to reduce vaso-occlusive crises (VOCs), transfusions, and hospitalizations, but its impact in resource-limited environments requires further investigation. Hence, this study aimed to assess the clinical and hematological effectiveness of hydroxyurea therapy in children and adolescents with sickle cell anaemia at Kenyatta National Hospital. A retrospective one-arm cohort design was used to review medical records of pediatric patients with sickle cell anaemia (≤ 16 years) who were treated with hydroxyurea at Kenyatta National Hospital between January 2020 and December 2023. Eligible patients had received hydroxyurea therapy for a minimum duration of six months and had at least 12 months of documented follow-up data. Clinical outcomes, including the frequency of vaso-occlusive crises, hospitalizations, acute chest syndrome, stroke events, and transfusion requirements, were assessed alongside hematological markers such as hemoglobin level, mean corpuscular volume, and reticulocyte count. Data were collected using a structured data abstraction tool adapted from previously published studies. Statistical analysis was conducted using IBM SPSS Statistics version 29, with one-way analysis of variance used to examine changes in clinical and hematological parameters across multiple follow-up time points. A total of 54 children and adolescents with sickle cell anaemia (mean age: 6.8 ± 4.4 years) were included, all of whom had a substantial burden of disease at baseline, marked by frequent vaso-occlusive crises (2.6 ± 1.9), hospital admissions (2.4 ± 2.0), blood transfusions (2.9 ± 1.7), and episodes of acute chest syndrome (1.3 ± 0.9). Over the 3, 6, 12, and 24-month follow-up period after initiation of hydroxyurea therapy, overall clinical outcomes showed a general decline in the proportion of patients experiencing vaso-occlusive crises, hospitalizations, transfusion needs, and infections compared with baseline. Hematological parameters demonstrated progressive improvement, with mean hemoglobin rising from 7.8 ± 1.1 g/dL at baseline to 10.5 ± 2.0 g/dL at 24 months, mean corpuscular volume increasing from 77.0 ± 21.1 fL to 96.7 ± 13.2 fL, and reticulocyte counts decreasing from 16.3 ± 11.9% to 6.0 ± 6.9%. Hydroxyurea therapy was associated with sustained improvements in hematological indices, characterized by increased hemoglobin levels and mean corpuscular volume, alongside a reduction in reticulocyte counts over the follow-up period. These changes were accompanied by reductions in key clinical complications, including vaso-occlusive crises and hospitalizations.</p></div>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"105 10","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13574882/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148337590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allogeneic hematopoietic stem cell transplantation for a pediatric case of myelodysplastic syndrome with germline DDX41 mutation","authors":"Tiantian Hu,&nbsp;Wenli Zhang,&nbsp;Teng Zhang,&nbsp;Man Wang,&nbsp;Zongxuan Huang,&nbsp;Yanling Tao","doi":"10.1007/s00277-026-07154-2","DOIUrl":"10.1007/s00277-026-07154-2","url":null,"abstract":"<div><p>According to the 2016 World Health Organization classifcation, a germline DEAD-box helicase 41 gene (DDX41) mutation with myeloid neoplasms(MNs) has been newly classifed. Such mutations are clearly linked to late-onset MNs, with patients typically presenting in middle to old age and often manifesting as high-risk AML or MDS. These patients are sensitive to hypomethylating agents, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently recognized as the curative treatment modality. However, pediatric cases of MNs associated with germline DDX41 mutations are extremely rare, resulting in significant gaps in understanding their clinical characteristics, treatment strategies, and prognostic data. This article reports a pediatric patient with high-risk myelodysplastic syndrome (MDS-EB-2) associated with a germline DDX41 mutation (c.316_320del) who underwent unrelated cord blood allogeneic hematopoietic stem cell transplantation. An 8-year-old female patient achieved bone marrow remission with azacitidine and venetoclax and subsequently underwent allogeneic hematopoietic stem cell transplantation from an unrelated umbilical cord blood donor, The conditioning regimen included fludarabine, decitabine, busulfan, and cyclophosphamide, leading to sustained donor engraftment. Post-transplant complications included HHV-6 encephalitis and grade III acute graft-versus-host disease (aGVHD) of the skin and gut, which were managed and controlled. At the 13-month follow-up, the patient remained in complete hematologic remission without recurrence. This case suggests that allo-HSCT is a feasible curative option for children with high-risk MDS and germline DDX41 predisposition, highlighting the critical importance of screening potential donors for the same mutation.</p></div>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"105 10","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13574888/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148337498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Socioeconomic deprivation, disease complications and access to preventive care in sickle cell disease in mainland France","authors":"Ondine Walter,&nbsp;Pierre Cougoul,&nbsp;Maryse Lapeyre-Mestre,&nbsp;Michelle Kelly-Irving,&nbsp;Margaux Lafaurie,&nbsp;Guillaume Moulis.","doi":"10.1007/s00277-026-07038-5","DOIUrl":"10.1007/s00277-026-07038-5","url":null,"abstract":"<div><p>Several studies have assessed the impact of socioeconomic factors on the health of sickle cell patients, yielding heterogeneous results. We conducted a population-based study using a health-insurance database in France to investigate this association, using longitudinal data over a 9-year follow-up time. Socioeconomic factors were assessed using the validated French deprivation index, an area-level index of social disadvantage. The study population comprised 17,315 patients with a median age of 23 years and a median follow-up of 8.1 years. Patients living in the most disadvantaged areas were at greater risk of vaso-occlusive events (VOEs): 70.4% of patients with a median cumulative time of hospitalization of 33.5 days over the study period in the disadvantaged socioeconomic group, compared to 67.9% of patients and 29.9 days in the comparison group (p = 0.035 and p &lt; 0.001). There was no difference regarding chronic complications, but a trend towards higher mortality in the disadvantaged group (HR: 1.13, 95% CI: 0.94—1.36). There was no difference between groups in access to preventive and curative care recommended in mainland France (vaccination, folic acid supplementation, antibiotic prophylaxis, hydroxycarbamide use).</p></div>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"105 10","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13574879/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148337567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune Effector Cell–associated Hemophagocytic Syndrome (IEC-HS) as a late immune-mediated toxicity after CAR-T therapy in Diffuse Large B-Cell Lymphoma (DLBCL): a case report","authors":"Sofía Rincón-López,&nbsp;Ricardo García-Muñoz,&nbsp;Johelys Atencio-Matos,&nbsp;Olalla Pereda-Sainz,&nbsp;Javier Larreina-Pérez,&nbsp;Andrea Campeny-Najara,&nbsp;Pilar Herrera Pérez,&nbsp;Montserrat Hernández-Pérez,&nbsp;Jesús Feliu,&nbsp;Ada Esteban-Figuerola","doi":"10.1007/s00277-026-07105-x","DOIUrl":"10.1007/s00277-026-07105-x","url":null,"abstract":"<div><p>Chimeric antigen receptor (CAR) T-cell therapy has dramatically improved the prognosis of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) [1,2]. However, immune-mediated toxicities represent a significant emerging clinical challenge, particularly those with late onset or uncommon presentations. We report the case of a 71-year-old woman with heavily pretreated DLBCL who developed immune effector cell–associated hemophagocytic syndrome (IEC-HS) with a fatal outcome six months following CAR-T infusion. This case highlights the occurrence of late -onset CAR-T-related toxicities and the potential role of CAR-T cell persistence in sustaining dysregulated immune activation.</p></div>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"105 10","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13572328/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148337501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and prognostic significance of concomitant autoimmune disease in patients with myelofibrosis","authors":"Alessandro Costa,&nbsp;Olga Mulas,&nbsp;Marianna Greco,&nbsp;Martina Piras,&nbsp;Gabriele Accossu,&nbsp;Federica Pilo,&nbsp;Giovanni Caocci","doi":"10.1007/s00277-026-07128-4","DOIUrl":"10.1007/s00277-026-07128-4","url":null,"abstract":"<div><p>There is growing interest in the association between autoimmune diseases (AID) and myeloproliferative neoplasms (MPN), yet the specific clinical and prognostic implications of AID in myelofibrosis (MF) remain insufficiently characterized. A retrospective analysis was conducted in patients diagnosed with primary MF (PMF) or secondary MF (SMF). Concomitant AID diagnoses were identified through medical record review and included only cases with documented clinical diagnosis. A total of 135 patients with MF were analyzed, including 90 (66.7%) with PMF and 45 (33.3%) with SMF. At diagnosis, 31 AID diagnoses were recorded in 29 patients (21.5%), of which 54.8% were organ-specific and 45.2% systemic. AID was more frequent in female patients (<i>p</i> = 0.005). At a median follow-up of 37.3 months, 3-year overall survival (OS) was 78%, with inferior OS in patients with systemic AID (61%; <i>p</i> = 0.028) compared to those without AID (79%) or with organ-specific AID (88%). In multivariable analysis, systemic AID (HR 2.16, p = 0.043), anemia (HR 1.79, <i>p</i> = 0.041), age (HR 1.08, <i>p</i> &lt; 0.001), and JAK-inhibitor therapy (HR 0.57, <i>p</i> = 0.023) independently predicted mortality. Severe infections and thrombotic events were more frequent in AID patients (26% vs 9.3%, <i>p</i> = 0.0082), with significance retained for infections alone (<i>p</i> = 0.016). The presence of AID did not affect the rate of leukemic transformation. Systemic AID identifies a subset of MF patients with worse survival and increased susceptibility to infections, supporting intensified surveillance and tailored management strategies in this population.</p></div>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"105 10","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13572334/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148337573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes with luspatercept in patients with β-thalassemia: a systematic review and meta-analysis","authors":"Nihal Babiker,&nbsp;Eslam Abady,&nbsp;Hafsa Shahid,&nbsp;Wania Ur Rehman,&nbsp;Faris Babker,&nbsp;Menna Sarhan,&nbsp;Hind El Azzazi,&nbsp;Mohamedelborae Abdalgafar Elimam Mohamed,&nbsp;Hafiz Muhammad Hannan Javed,&nbsp;Yahya Samadi","doi":"10.1007/s00277-026-07151-5","DOIUrl":"10.1007/s00277-026-07151-5","url":null,"abstract":"<div><p>β-thalassaemia is a genetic blood disorder characterized by ineffective erythropoiesis and chronic anaemia, often requiring lifelong red blood cell (RBC) transfusions. Luspatercept, an erythroid maturation agent, has emerged as a potential therapy to reduce transfusion burden in affected adults. To assess the clinical efficacy and safety of luspatercept in managing adult patients with β-thalassemia. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating luspatercept in adult patients with β-thalassemia. A comprehensive search of PubMed, Scopus, Embase, Cochrane Library, and ClinicalTrials.gov was performed for studies published up to May 2025. Only English-language RCTs were included. Data were extracted on transfusion burden, hemoglobin response, and adverse events. Risk of bias was assessed using the Cochrane ROB 2 tool. Pooled estimates were calculated using a random-effects model with the Freeman–Tukey double arcsine transformation. Heterogeneity was assessed using the I² statistic. Out of 587 identified records, three RCTs and one single-arm trial (<i>n</i> = 608 patients) met the inclusion criteria. Of these, 447 patients received luspatercept and 161 received placebo. Luspatercept was associated with a ≥ 33% reduction in RBC transfusion burden in 58% (95% CI: 0.33–0.79) and a ≥ 50% reduction in 40% (95% CI: 0.25–0.58) of patients. Transfusion independence was achieved in 36% (95% CI: 0.13–0.69). Common adverse events included headache (32%), bone pain (33%), arthralgia (22%), and back pain (20%). Grade ≥ 3 adverse events occurred in 21% (95% CI: 0.09–0.41). Overall, luspatercept effectively reduced transfusion needs with an acceptable safety profile. Luspatercept significantly reduces transfusion burden in patients with β-thalassemia and demonstrates a manageable safety profile. These findings support luspatercept as an effective and well-tolerated therapeutic option that meaningfully reduces transfusion burden, potentially decreasing iron overload and improving quality of life for patients with β-thalassemia.</p></div>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"105 10","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00277-026-07151-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148325797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting response to hypomethylating agents in myeloid neoplasms: a robust model","authors":"Chao Guo,&nbsp;Ya-yue Gao,&nbsp;Qian-qian Ju,&nbsp;Zhen-ling Li","doi":"10.1007/s00277-026-07137-3","DOIUrl":"10.1007/s00277-026-07137-3","url":null,"abstract":"<div><p>Current biomarkers and prognostic systems lack sufficient evaluation of their predictive power on HMA efficacy for myeloid neoplasms. Weighted Gene Co-expression Network Analysis (WGCNA) was employed to uncover the target module correlated with HMA response. Based on this module, Least Absolute Shrinkage and Selection Operator (LASSO) regression was applied to establish a predictive model with non-zero coefficients, termed the HMA-29 model. The magenta module was identified as the target module correlating with HMA response (R² = 0.37, <i>p</i> = 2 × 10⁻⁴). LASSO regression established the HMA-29 model, comprising the expression signatures of 29 genes, which stratified patients into responsive-like and resistant-like groups. HMA-29 risk scores significantly differed between HMA responders and non-responders and demonstrated superior predictive performance (AUC 0.9982, <i>p</i> &lt; 0.0001). The predictive capability was validated across independent cohorts/disease subtypes/HMA drugs/sampling conditions. Notably, HMA-29 risk scores did not significantly differ between pre- and post-treatment samples. Moreover, Kaplan-Meier analysis demonstrated significant differences of disease-free survival (DFS) and overall survival (OS) between the HMA-29-defined groups. GSEA indicated that the G2M checkpoint, MYC targets, and E2F targets were positively associated with HMA-29 risk. We developed a novel predictive model for HMA response in myeloid neoplasms, demonstrating superior predictive and prognostic value compared to existing systems. Our findings provide insights into potential therapeutic strategies, including the integration of targeted therapies with HMA treatment.</p></div>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"105 10","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00277-026-07137-3.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148306662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of age and primary treatment with risk of non-lymphoma-related death and long-term survival outcomes in adult patients with early-stage follicular lymphoma: a population-based analysis","authors":"Chang Xu,&nbsp;Yunpeng Wu,&nbsp;Xin Liu,&nbsp;Qiu-Zi Zhong,&nbsp;Yong Yang,&nbsp;Tao Wu,&nbsp;Si-Ye Chen,&nbsp;Bo Chen,&nbsp;Yong-Wen Song,&nbsp;Hui Fang,&nbsp;Jing Jin,&nbsp;Yue-Ping Liu,&nbsp;Hao Jing,&nbsp;Yuan Tang,&nbsp;Ning Li,&nbsp;Ning-Ning Lu,&nbsp;Wen-Wen Zhang,&nbsp;Shu-Lian Wang,&nbsp;Jingru Zhu,&nbsp;Shu-Nan Qi,&nbsp;Ye-Xiong Li","doi":"10.1007/s00277-026-07144-4","DOIUrl":"10.1007/s00277-026-07144-4","url":null,"abstract":"<div><p>In adult patients with early-stage follicular lymphoma (FL), age-related differences in the risk of non-lymphoma-related death (LRD) during the follow-up period after treatment are unclear. We aimed to investigate the interactive effects of age and primary treatment on the risk of non-LRD and survival. We retrospectively analyzed the data of 6030 adult patients with early-stage FL from the Surveillance, Epidemiology, and End Results (SEER) database (2000–2020). Primary therapy involved observation (<i>n</i> = 2509), chemotherapy (CT) alone (<i>n</i> = 1844), radiotherapy alone (RT, <i>n</i> = 1191) or RT and CT (RT + CT, <i>n</i> = 486). The groups were balanced by inverse probability of treatment weighting (IPTW). Comparisons of the cumulative incidence of non-LRD were performed using competing-risk analysis and transformed Cox regression analysis. The median patient age was 64 years (RT, 62 years; RT + CT, 60 years; CT, 63 years; observation, 66 years). Over a median follow-up period of 132 months, 830 patients (13.8%) died of FL, while non-LRD accounted for 1279 patients (21.2%). Age significantly influenced the non-LRD risk, especially in patients aged &gt; 60 years. After IPTW adjustment, RT alone, RT + CT or CT alone was not associated with an increased risk of the cumulative incidences of non-LRD or its specific causes in comparison with observation. Age-dependent analyses showed that the adjusted hazard ratios (HRs) for RT alone, RT + CT or CT versus observation remained close to 1.0 across the age spectrum, indicating no significant difference in non-LRD risk between treatment groups. RT alone and RT + CT conferred sustained overall survival (OS), disease specific survival (DSS) and relative survival (RS) advantages over CT or observation, with RS consistently exceeding 90% over the extended follow-up period. The survival benefit of RT versus non-RT persisted across age groups, with the adjusted HRs for OS and RS remaining below 1.0 for most ages. Older age, not primary treatment, was associated with an increased risk of non-LRD. The results indicated the safety and long-term survival benefit of RT in adult patients with early-stage FL.</p></div>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"105 9","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00277-026-07144-4.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148306681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Between the classic hit and the modern sequel: transition dosing between peginterferon alfa-2a and ropeginterferon alfa-2b for myeloproliferative neoplasms","authors":"Ghaith Abu-Zeinah,&nbsp;Gabriela Hobbs,&nbsp;Brandi N. Reeves,&nbsp;Abdulraheem Yacoub,&nbsp;Joseph M. Scandura","doi":"10.1007/s00277-026-07143-5","DOIUrl":"10.1007/s00277-026-07143-5","url":null,"abstract":"","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"105 7","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00277-026-07143-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148306676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase I study of oral azacitidine plus salvage chemotherapy in relapsed/refractory diffuse large B-cell lymphoma","authors":"Brian Hess,&nbsp;Nina D. Wagner-Johnston,&nbsp;Lindsey Hendrickson,&nbsp;James A. Davis,&nbsp;Elizabeth Hill,&nbsp;Anshu Giri,&nbsp;Kent Armeson,&nbsp;Maria V. Revuelta,&nbsp;Shanta Salzer,&nbsp;Robin Klingenberg,&nbsp;Leandro Cerchietti","doi":"10.1007/s00277-026-07125-7","DOIUrl":"10.1007/s00277-026-07125-7","url":null,"abstract":"<div><p>Salvage chemotherapy and autologous stem cell transplantation (ASCT) offer the opportunity to cure eligible patients with relapsed diffuse large B-cell lymphoma (DLBCL). Epigenetic alterations such as aberrant DNA methylation patterns have been linked to chemotherapy resistance in DLBCL. Oral Azacitadine (AZA) is a hypomethylating agent that inhibits DNA methyltransferase and has provided evidence of chemotherapy sensitization in DLBCL. In this phase I trial the safety and feasibility of two dose levels of AZA were investigated in combination with standard cytotoxic chemotherapy rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in relapsed DLBCL patients who were candidates for ASCT.</p></div>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"105 9","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13538234/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148293304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}